Literature DB >> 8613056

Risk of primary sclerosing cholangitis is associated with nonsmoking behavior.

K J van Erpecum1, S J Smits, P C van de Meeberg, F H Linn, F H Wolfhagen, G P vanBerge-Henegouwen, A Algra.   

Abstract

BACKGROUND & AIMS: Seventy percent of patients with primary sclerosing cholangitis (PSC) have concomitant ulcerative colitis. Smoking and previous appendectomy may protect against ulcerative colitis. The aim of this study was to examine these factors in patients with PSC.
METHODS: Fifty-nine patients with PSC, 130 patients with ulcerative colitis and normal liver biochemistry, and 197 control subjects were interviewed about smoking behavior and history of appendectomy.
RESULTS: There were less current smokers in the PSC and ulcerative colitis groups than in the control group (19%, 12%, and 38%, respectively). The resulting odds ratio for current smoking was 0.37 (95% confidence interval, (0.18-0.76) in the PSC group and 0.23 (95% confidence interval, 0.13-0.41) in the ulcerative colitis group. Percentage of persons who ever smoked was also significantly less in the PSC group (41% vs. 56% in the control group). Frequency of previous appendectomy in the PSC and ulcerative colitis groups was not significantly different from that of controls (19%, 9%, and 14%, respectively).
CONCLUSIONS: Smoking but not previous appendectomy is associated with decreased risk of PSC.

Entities:  

Mesh:

Year:  1996        PMID: 8613056     DOI: 10.1053/gast.1996.v110.pm8613056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Lack of effect of transdermal nicotine on 3 cases of primary sclerosing cholangitis.

Authors:  G Jørgensen; H L Waldum
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 2.  Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

Authors:  R T Prall; K D Lindor; R H Wiesner; N F LaRusso
Journal:  Curr Gastroenterol Rep       Date:  2000-04

Review 3.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

4.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.

Authors:  S A Mitchell; M Thyssen; T R Orchard; D P Jewell; K A Fleming; R W Chapman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 5.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

6.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

7.  Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Harry Sokol; Jacques Cosnes; Olivier Chazouilleres; Laurent Beaugerie; Emmanuel Tiret; Raoul Poupon; Philippe Seksik
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 8.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 9.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases.

Authors:  T H J Florin; N Pandeya; G L Radford-Smith
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.